LAMIVUDINE = 3TC oral

Select language:
On this page

     

    Prescription under medical supervision

     

    Therapeutic action

    • Antiretroviral, HIV-1 and HIV-2 nucleoside reverse transcriptase inhibitor

    Indications

    • HIV-1 or HIV-2 infection, in combination with other antiretroviral drugs

    Forms and strengths

    • 150 mg and 300 mg tablets
    • 50 mg/5 ml oral solution

    Dosage

    • Child under 1 month: 2 mg/kg 2 times daily 
    • Child from 1 month to 12 years: 4 mg/kg 2 times daily
    • Adult: 300 mg once daily 

     

    Weight

    10 mg/ml oral sol.

    150 mg tablet

    300 mg tablet

    5 to 9 kg

    2.5 ml x 2

    10 to 14 kg

    5 ml x 2

    15 to 19 kg

    7 ml x 2

    ½ tab x 2

    20 to 24 kg

    9 ml x 2

    ½ tab x 2

    25 to 29 kg

    11 ml x 2

    2 tab

    1 tab

    ≥ 30 kg

    2 tab

    1 tab

     

    Duration

    • The duration of treatment depends on the efficacy and tolerance of lamivudine.

    Contra-indications, adverse effects, precautions

    • Administer with caution to patients with history of hepatic disorders.
    • May cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly: haematological disorders, especially when combined with zidovudine (neutropenia, anaemia, thrombocytopenia), myopathy, hepatic or pancreatic disorders.
    • Reduce dosage in patients with renal impairment.
    • Pregnancy: no contra-indication

    Remarks

    • For prophylactic treatment to reduce mother-to-child HIV transmission, check national recommendations.
    • Many fixed-dose combinations containing lamivudine are available.

    Storage

    Below 25 °C
    Once opened, oral solution keeps for 30 days maximum.